Search Results - "Yip, Terry Cheuk‐Fung"
-
1
Angiotensin‐converting enzyme inhibitors prevent liver‐related events in nonalcoholic fatty liver disease
Published in Hepatology (Baltimore, Md.) (01-08-2022)“…Background and Aims Angiotensin‐converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) can inhibit liver fibrogenesis in animal models…”
Get full text
Journal Article -
2
An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: A Territory‐Wide Study From 2000 to 2017
Published in Hepatology (Baltimore, Md.) (01-02-2020)“…Patients with chronic hepatitis B (CHB) are aging because of improved survival under better health care. This has an important implication on the choice of…”
Get full text
Journal Article -
3
Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID‐19
Published in Hepatology (Baltimore, Md.) (01-10-2021)“…Background and Aims We compared risk of acute liver injury and mortality in patients with COVID‐19 and current, past, and no HBV infection. Approach and…”
Get full text
Journal Article -
4
Liver stiffness measurement predicts long‐term survival and complications in non‐alcoholic fatty liver disease
Published in Liver international (01-03-2020)“…Background and aims In non‐alcoholic fatty liver disease (NAFLD), fibrosis is the strongest prognostic factor and can be assessed by non‐invasive methods. We…”
Get full text
Journal Article -
5
Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis
Published in Alimentary pharmacology & therapeutics (01-11-2019)“…Summary Background Lamivudine and entecavir reduce hepatic events and death in chronic hepatitis B (CHB) patients with cirrhosis, but the impact of tenofovir…”
Get full text
Journal Article -
6
Risk of severe infection in patients with non‐alcoholic fatty liver disease: Implication on clinical management
Published in Liver international (01-10-2023)Get full text
Journal Article -
7
Risk of liver‐related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease
Published in Hepatology (Baltimore, Md.) (01-11-2022)“…Background and Aims Several guidelines recommend screening for NAFLD in patients with type 2 diabetes (T2D). We aimed to determine if there is a threshold of…”
Get full text
Journal Article -
8
Editorial: Can liver fat quantification stratify cardiovascular risk in type 2 diabetes?
Published in Alimentary pharmacology & therapeutics (01-11-2023)“…LINKED CONTENT This article is linked to Kuo et al papers. To view these articles, visit https://doi.org/10.1111/apt.17637 and https://doi.org/10.1111/apt.17742…”
Get full text
Journal Article -
9
Editorial: central obesity is a risk factor for hepatocellular carcinoma in Asian patients with chronic hepatitis B on anti‐viral therapy
Published in Alimentary pharmacology & therapeutics (01-09-2021)“…LINKED CONTENT This article is linked to Fan et al and Fan & Hou papers. To view these articles, visit https://doi.org/10.1111/apt.16469 and…”
Get full text
Journal Article -
10
Editorial: improvement of cardiovascular risk factor control in patients with type 2 diabetes and nonalcoholic fatty liver disease—time for action! Authors' reply
Published in Alimentary pharmacology & therapeutics (01-05-2023)“…LINKED CONTENT This article is linked to Zhang et al papers. To view these articles, visit https://doi.org/10.1111/apt.17428 and…”
Get full text
Journal Article -
11
Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment
Published in Alimentary pharmacology & therapeutics (01-11-2018)“…Summary Background In clinical trials involving patients with preserved renal function, tenofovir disoproxil fumarate (TDF) use was associated with mild renal…”
Get full text
Journal Article -
12
Letter: vaccination for global control of hepatitis B—from prevention to elimination. Authorsʼ reply
Published in Alimentary pharmacology & therapeutics (01-12-2022)“…LINKED CONTENT This article is linked to Wong et al papers. To view these articles, visit https://doi.org/10.1111/apt.17120 and…”
Get full text
Journal Article -
13
MAFLD fibrosis score: Using routine measures to identify advanced fibrosis in metabolic-associated fatty liver disease
Published in Alimentary pharmacology & therapeutics (01-12-2023)“…Early screening may prevent fibrosis progression in metabolic-associated fatty liver disease (MAFLD). We developed and validated MAFLD fibrosis score (MFS) for…”
Get full text
Journal Article -
14
CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance
Published in Alimentary pharmacology & therapeutics (01-05-2024)“…Summary Background Risk of hepatocellular carcinoma (HCC) persists after hepatitis B surface antigen (HBsAg) seroclearance in patients with chronic hepatitis B…”
Get full text
Journal Article -
15
Risk and predictors of hepatic decompensation in grey zone patients by the Baveno VII criteria: A competing risk analysis
Published in Alimentary pharmacology & therapeutics (01-11-2023)“…Summary Background Baveno VII was proposed for non‐invasive identification of clinically significant portal hypertension. However, a substantial proportion of…”
Get full text
Journal Article -
16
Letter: systematic review with meta‐analysis on the impact of functional cure on clinical outcomes in patients with chronic hepatitis B
Published in Alimentary pharmacology & therapeutics (01-03-2022)“…LINKED CONTENT This article is linked to Vittal et al papers. To view these articles, visit https://doi.org/10.1111/apt.16659 and…”
Get full text
Journal Article -
17
Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue‐induced hepatitis B surface antigen loss
Published in Alimentary pharmacology & therapeutics (01-01-2021)“…Summary Background It is unknown whether patients with chronic hepatitis B (CHB) who achieved hepatitis B surface antigen (HBsAg) seroclearance spontaneously…”
Get full text
Journal Article -
18
Machine learning model to predict recurrent ulcer bleeding in patients with history of idiopathic gastroduodenal ulcer bleeding
Published in Alimentary pharmacology & therapeutics (01-04-2019)“…Summary Background Patients with a history of Helicobacter pylori–negative idiopathic bleeding ulcers have an increased risk of recurring ulcer complications…”
Get full text
Journal Article -
19
Serum PRO‐C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort
Published in Liver international (01-05-2024)“…Background Metabolic dysfunction‐associated fatty liver disease (MAFLD) is an emerging risk factor for chronic kidney disease (CKD). N‐terminal propeptide of…”
Get full text
Journal Article -
20
HCC risk reduction with oral nucleos(t)ide analogues in patients with chronic hepatitis B: Not perfect, not good enough
Published in Journal of gastroenterology and hepatology (01-10-2020)Get full text
Journal Article